On Wednesday, Shares of Micron Technology, Inc. (NASDAQ:MU), gained 3.52% to $18.82, as the company starts talks with chipmaker SanDisk (SNDK) about a possible acquisition. Bloomberg reports.
The stock attained the volume of 34.62 million shares.
SanDisk is statedly in talks with Western Digital (WDC) as well, but the negotiations will not necessarily result in a deal with either Micron or Western Digital, sources told Bloomberg.
A merger deal between SanDisk and Micron could be complicated by a decade-long partnership Micron has with Intel (INTC), Deepon Nag, analyst at Macquarie Group, said in a note, according to Bloomberg.
In other news, Lexar, a leading global brand of flash memory products, declared two additions to its mobile USB 3.0 flash drive line: the Lexar(R) JumpDrive(R) M20c and the Lexar JumpDrive M20i. The Lexar JumpDrive M20c is designed for use with next-generation USB Type-C devices, and features two connectors — USB Type-C and USB 3.0 — to allow users to easily share content between smartphones, tablets, and computers. The Lexar JumpDrive M20i is designed for use with iOS devices, enabling users to easily offload and move photos and videos between an iPhone(R), iPad(R), and computers.
Lexar JumpDrive M20c
The Lexar JumpDrive M20c leverages USB 3.0 performance with up to 150MB/s read and 60MB/s write speeds.* Users can transfer a 3GB HD video clip in less than one minute, contrast to the four minutes it takes using a standard USB 2.0 drive.*** Its reversible design of the Type-C connector means no fumbling to insert it correctly. It also easily expands the memory of your devices providing more room for your favorite images and videos. For added versatility, the drive is backwards compatible with USB 2.0 devices.
Lexar JumpDrive M20i
The Lexar JumpDrive M20i drive features a Lightning(R) and USB 3.0 connector, making quick work of offloading files on the go—no charging or battery needed, and no network required. It operates with the use of a free file administration app from the App Storewhich allows users to back up files when connected, and automatically and securely syncs files on the go. The JumpDrive M20i provides read speeds up to 95MB/s and write speeds up to 20MB/s.** For added versatility, the drive is backwards compatible with USB 2.0 devices.
Lexar is a global brand of Micron Consumer Products Group, Inc., a partner of Micron Technology, Inc.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
At the end of Wednesday’s trade, Shares of Kroger Co (NYSE:KR), declined -2.96% to $36.33.
Kroger Co. investors haven’t had much to complain about lately, but the stock has been in a bit of a slump. That might be concerning to shareholders, but it won’t last long, one analyst says.
Shares in Cincinnati-based Kroger (NYSE: KR) are set to bounce back and rally to their new highs, investor and analyst Josh Arnold wrote in a recent article on investment website Seeking Alpha, according to Business Journals.
Arnold, a certified Seeking Alpha contributor, said Kroger’s stock has been stuck in a fairly tight range much of the year. The stock’s sideways move “has given way to chaotic selloffs and rallies,” he said.
He sees the positives of same-store sales growth and rising fuel margins as bullish signs for the nation’s largest operator of traditional supermarkets. Business Journals Reports
As part of their Diabetes Awareness Month activities, supermarket partners Ralphs and Food 4 Less are inviting their customers to be part of the Stop Diabetes® movement.
November is Diabetes Awareness Month and from October 14 through November 10, Ralphs and Food 4 Less are offering their customers the opportunity to assist in the fight to stop diabetes by donating their spare change in specially-marked coin boxes located at the check stands in all Ralphs and Food 4 Less stores in Southern California. Also collecting funds to assist stop diabetes will be 14 Food 4 Less stores serving the greater Chicago area, and 22 Foods Co stores serving Central and Northern California.
All funds raised will be donated to the American Diabetes Association (ADA) in support of its mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
Ralphs is a partner of The Kroger Co., (KR).
The Kroger Co., together with its auxiliaries, operates as a retailer in the United States and internationally. It also manufactures and processes food for sale in its supermarkets. The company operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores.
Finally, Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), ended its last trade with -11.78% loss, and closed at $29.06.
An FDA advisory board won’t meet to review the potential drug to treat Duchenne muscular dystrophy developed at Sarepta Therapeutics until nearly two months later than most patient advocates predictable, nixing the hope that it might be approved before the end of this year, according to Business Journals.
That two-month delay appears to be behind a 5 percent stock drop in shares of Sarepta (Nasdaq SRPT) recently as of 2:30 p.m., shaving about $70 million off the company’s market value.
Sarepta recently confirmed the date of Jan. 22, 2016 for a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee, the committee which would review its drug. BioMarin Pharmaceutical (Nasdaq: BMRN), the California-based drug company is hoping for approval of a drug aimed at the same patient population as Sarepta, recently declared that the FDA has said it will review its drug on Nov. 24.
While FDA advisory committees do not make the final decision on approval of the drug, the agency usually follows the recommendations they make, so a positive vote at a so-called AdComm meeting almost always means the drug will be approved within a few weeks or months. Business Journals Reports
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
